EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.75 USD | +0.91% |
|
-2.55% | +15.08% |
| Apr. 23 | Edwards Lifesciences Corporation: The story continues |  |
| Apr. 17 | Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 | MT |
Financials (USD)
| Sales 2024 * | 6.52B | Sales 2025 * | 7.15B | Capitalization | 52.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.82B | EV / Sales 2024 * | 7.82 x |
| Net cash position 2024 * | 1.87B | Net cash position 2025 * | 3.09B | EV / Sales 2025 * | 6.95 x |
| P/E ratio 2024 * |
32.7
x | P/E ratio 2025 * |
29.2
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | +0.91% | ||
| 1 week | -2.55% | ||
| Current month | -8.17% | ||
| 1 month | -6.44% | ||
| 3 months | +17.27% | ||
| 6 months | +27.08% | ||
| Current year | +15.08% |
1 week
85.38
87.93
1 month
85.3896.12
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
| Chairman | 71 | 99-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Director/Board Member | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 44 M€ | +0.77% | - | |
| 2.34% | 18 M€ | +4.24% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 87.75 | +0.91% | 2,663,641 |
| 24-04-22 | 86.96 | +1.19% | 2,408,082 |
| 24-04-19 | 85.94 | -0.59% | 3,895,701 |
| 24-04-18 | 86.45 | -0.91% | 3,122,037 |
| 24-04-17 | 87.24 | -3.12% | 2,878,118 |
Delayed Quote Nyse, April 23, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
87.75
USD
Average target price
94.48
USD
Spread / Average Target
+7.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.08% | 52.82B | |
| +8.35% | 219B | |
| +9.41% | 187B | |
| +11.75% | 134B | |
| +19.34% | 101B | |
| +0.61% | 62.27B | |
| -2.10% | 47.49B | |
| +0.10% | 40.79B | |
| +11.50% | 39.35B | |
| +7.11% | 27.06B |
- Stock Market
- Equities
- EW Stock
